New hope for transplant patients with life-threatening immune attack
Disease control
Not yet recruiting
This study tests whether adding a special cell therapy (remestemcel-L) to standard treatment (ruxolitinib) can help adults with severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a serious complication where donor immune cells attack the patient's …
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Disease control
Last updated May 17, 2026 07:22 UTC